Results 31 to 40 of about 9,817 (177)

SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity. [PDF]

PLoS ONE, 2017
The heat shock response (HSR) is a well-conserved, cytoprotective stress response that activates the HSF1 transcription factor. During severe stress, cells inhibit mRNA splicing which also serves a cytoprotective function via inhibition of gene ...
Karen S Kim Guisbert, Eric Guisbert
doaj   +1 more source

Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells

Artificial Cells, Nanomedicine, and Biotechnology, 2019
Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3b1 subunit of the spliceosome. There is considerable interest in the compound as a tool to study SF3b1 function in cancer.
Qianjing Zhang, Cuixia Di, Junfang Yan, Fang Wang, Tao Qu, Yupei Wang, Yuhong Chen, Xuetian Zhang, Yang Liu, Hongying Yang, Hong Zhang   +10 more
doaj   +1 more source

Rare SF3B1 R625 mutations in cutaneous melanoma [PDF]

Melanoma Research, 2014
RNA splicing is the cellular process that has only recently been found to be an important target for various cancers. Among the spliceosome genes that are involved in cancers, SF3B1 is most frequently mutated. Recurrent mutation in codon 625 has been found in uveal melanoma, but this mutation has not been identified in cutaneous melanoma. We used whole-
Yong, Kong, Michael, Krauthammer, Ruth, Halaban   +2 more
openaire   +2 more sources

Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. [PDF]

PLoS Computational Biology, 2015
Mutations in the splicing factor SF3B1 are found in several cancer types and have been associated with various splicing defects. Using transcriptome sequencing data from chronic lymphocytic leukemia, breast cancer and uveal melanoma tumor samples, we ...
Christopher DeBoever, Emanuela M Ghia, Peter J Shepard, Laura Rassenti, Christian L Barrett, Kristen Jepsen, Catriona H M Jamieson, Dennis Carson, Thomas J Kipps, Kelly A Frazer   +9 more
doaj   +1 more source

Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability

eLife, 2017
Genomic instability is a hallmark of human cancer, and results in widespread somatic copy number alterations. We used a genome-scale shRNA viability screen in human cancer cell lines to systematically identify genes that are essential in the context of ...
Brenton R Paolella, William J Gibson, Laura M Urbanski, John A Alberta, Travis I Zack, Pratiti Bandopadhayay, Caitlin A Nichols, Pankaj K Agarwalla, Meredith S Brown, Rebecca Lamothe, Yong Yu, Peter S Choi, Esther A Obeng, Dirk Heckl, Guo Wei, Belinda Wang, Aviad Tsherniak, Francisca Vazquez, Barbara A Weir, David E Root, Glenn S Cowley, Sara J Buhrlage, Charles D Stiles, Benjamin L Ebert, William C Hahn, Robin Reed, Rameen Beroukhim   +26 more
doaj   +1 more source

Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1

Molecular Oncology, 2023
Mutations in the splicing factor 3b subunit 1 (SF3B1) gene are frequent in myelodysplastic neoplasms (MDS). Because the splicing process is involved in the production of circular RNAs (circRNAs), we investigated the impact of SF3B1 mutations on circRNA ...
Iva Trsova, Andrea Hrustincova, Zdenek Krejcik, David Kundrat, Aleš Holoubek, Karolina Staflova, Lucie Janstova, Sarka Vanikova, Katarina Szikszai, Jiri Klema, Petr Rysavy, Monika Belickova, Monika Kaisrlikova, Jitka Vesela, Jaroslav Cermak, Anna Jonasova, Jiri Dostal, Jan Fric, Jan Musil, Michaela Dostalova Merkerova   +19 more
doaj   +1 more source

SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts [PDF]

New England Journal of Medicine, 2011
Myelodysplastic syndromes are a diverse and common group of chronic hematologic cancers. The identification of new genetic lesions could facilitate new diagnostic and therapeutic strategies.We used massively parallel sequencing technology to identify somatically acquired point mutations across all protein-coding exons in the genome in 9 patients with ...
Papaemmanuil, E, Cazzola, M, Boultwood, J, Malcovati, L, Vyas, P, Bowen, D, Pellagatti, A, Wainscoat, JS, Hellstrom Lindberg, E, GAMBACORTI PASSERINI, CARLO, Godfrey, AL, Rapado, I, Cvejic, A, Rance, R, McGee, C, Ellis, P, Mudie, LJ, Stephens, PJ, McLaren, S, Massie, CE, Tarpey, PS, Varela, I, Nik Zainal, S, Davies, HR, Shlien, A, Jones, D, Raine, K, Hinton, J, Butler, AP, Teague, JW, Baxter, EJ, Score, J, Galli, A, Della Porta, MG, Travaglino, E, Groves, M, Tauro, S, Munshi, NC, Anderson, KC, El Naggar, A, Fischer, A, Mustonen, V, Warren, AJ, Cross, NC, Green, AR, Futreal, PA, Stratton, MR, Campbell, PJ, Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium   +48 more
openaire   +4 more sources

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αPDL1 in ovarian cancer

Cell Death and Disease, 2023
Ovarian cancer is resistant to immune checkpoint blockade (ICB) treatment. Combination of targeted therapy and immunotherapy is a promising strategy for ovarian cancer treatment benefit from an improved immune microenvironment.
Shourong Wang, Yao Liu, Huimin Xiao, Zhongshao Chen, Xiaohang Yang, Jingjing Yin, Yingwei Li, Cunzhong Yuan, Shi Yan, Gang Chen, Qinglei Gao, Beihua Kong, Chaoyang Sun, Kun Song   +13 more
doaj   +1 more source

Aging Is a Key Driver for Adult Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley   +1 more source